 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Vedolizumab.
|
Cost
editVedolizumab (Entyvio) is one of those very expensive drugs that insurers often refuse to authorize. It was discussed in a story in ProPublica:
https://www.propublica.org/article/unitedhealth-healthcare-insurance-denial-ulcerative-colitis
UnitedHealthcare Tried to Deny Coverage to a Chronically Ill Patient. He Fought Back, Exposing the Insurer’s Inner Workings.
by David Armstrong, Patrick Rucker and Maya Miller
ProPublica
2 February 2023
It's hard to get a meaningful price for an expensive drug, but one reported figure in a WP:MEDRS was $406,629:
The Cost-Effectiveness of Vedolizumab for Inflammatory Bowel Disease: A Review of the Current Literature
Gastroenterology & Hepatology
October 2016 12(10):617-621
Yecheskel Schneider, Monica Saumoy, Shirley Cohen-Mekelburg, Adam F. Steinlauf, and Ellen J. Scherl
--Nbauman (talk) 14:13, 28 June 2023 (UTC)
- @Nbauman - Your comment implies that the drug costs much more than it does. It is pricey, alright, but per the Gastroenterology and Hepatology article you reference, the cost of vedolizumab was $301,969/MH. "MH" is defined as "The goals of biologic therapy are mucosal healing (MH) and reversal of the natural history of progressive structural damage due to chronic inflammation." That could happen over months or years.
- Thank you, Wordreader (talk) 06:02, 27 December 2023 (UTC)